Successful treatment of relapsed acute promyelocytic leukemia with arsenic trioxide in a hemodialysis-dependent patient: A case report

作     者：Hee Jeong Lee Sang-Gon Park 

作者机构：Department of Hemato-OncologyChosun University HospitalGwang-ju 501-717South Korea Department of Internal MedicineHemato-oncologyChosun University HospitalGwangju 61453South Korea 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2020年第8卷第21期

页      面：5347-5352页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by Research fund from Chosun University 2020 

主　　题：Arsenic trioxide Acute promyelocytic leukemia Pancytopenia Hemodialysis Promyelocytic leukemia/retinoic acid receptor-αfusion gene Case report 

摘      要：BACKGROUND Arsenic trioxide(ATO)is recommended for patients who do not achieve molecular remission or who have molecular or morphologic ***,there are no guidelines for adjusting ATO dosage in patients with severe renal failure or on ***,we report the successful treatment of relapsed acute promyelocytic leukemia(APL)in a patient on hemodialysis with ATO single agent and review the cases in *** SUMMARY A 46-year-old woman who has been on hemodialysis to chronic glomerulonephritis for 15 years visited our hospital for *** had been seen for pancytopenia 3 years ago and had been diagnosed with *** also received chemotherapy for APL but unfortunately was lost to follow-up after her second consolidation *** was noted to have pancytopenia by her nephrologist during hemodialysis 1 mo *** marrow biopsy and reverse transcriptase-polymerase chain reaction(RT-PCR)tests revealed a diagnosis of relapsed *** for relapsed APL with ATO single agent was started and she achieved molecular remission after administering 24 doses of *** far,four consolidation therapies have been performed with the ATO single agent,and,to date,the molecular remission has been maintained as negative promyelocytic leukemia/retinoic acid receptor-αfusion gene as confirmed by RTPCR testing for two *** This is a rare case of relapsed APL successfully treated with the single agent ATO in a patient on hemodialysis.